Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that isorhamnetin, a compound from the Rampai plant, showed a lower affinity energy in molecular docking tests compared to Minoxidil, indicating potential as an androgen receptor antagonist for alopecia therapy in silico, with favorable pharmacokinetic characteristics in ADME-Tox predictions.

This review discusses human epidermal neural crest stem cells (hEPI-NCSC) as candidates for cell-based therapies and drug discovery but reports no new experimental results.

This ongoing study is exploring the potential effectiveness of Adiantum capillus-veneris, a medicinal herb, in treating COVID-19 symptoms, but it reports no new results yet.

This literature review compiles and analyzes current research on turmeric essential oil's active compounds, reporting their potential therapeutic applications across various medical conditions due to their unique pharmacological profiles and absence of toxicity.

Natural products might help treat hair greying.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

This study suggests a decision tree using in vitro metabolic clearance to identify early drug candidates likely to experience nonlinear pharmacokinetics due to intestinal CYP3A-related metabolism.

This study found that niosomes significantly enhanced the skin deposition of retinoic acid while reducing its permeation, outperforming other tested nanoformulations.

This study identified robust susceptibility genes and potential drug candidates for male-pattern baldness, providing insights into the condition's molecular mechanisms.

In this study, researchers developed a computational method called iEdgePathDDA that prioritizes anticancer drug candidates by analyzing changes in gene interactions, demonstrating superior performance compared to existing methods across colorectal, breast, and lung cancer datasets.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.

This review suggests that the compound DRDE-07, originally a sulphur-mustard countermeasure candidate, could potentially be repurposed for skin protection due to its compatibility with pathways involved in oxidative stress and inflammation, though further experimental study is needed to confirm its therapeutic applicability in dermatology.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

This study identified key genes linked to immune cells and potential therapeutic compounds for alopecia areata by evaluating upregulated genes from patient datasets, highlighting T and NK cell involvement in hair follicle attack and suggesting drug candidates through molecular docking and dynamics simulations.

This review highlights cepharanthine as a promising candidate for COVID-19 treatment due to its antiviral activity against SARS-CoV-2 and favorable pharmacokinetic and safety profile, but reports no new clinical results.

This review outlines computational strategies, including chemogenomics and drug repositioning, for coronavirus drug discovery and reports no new clinical findings; the authors highlight the advantages of these methods in rapidly identifying therapeutic candidates.

This study identified ten potential therapeutic targets and biomarkers for androgenic alopecia, with SOD1 and KL as particularly promising candidates for future therapies.

In this study, the researchers identified that perturbing both AKT1 and MDM2 significantly reduces epithelial-mesenchymal transition in melanoma, proposing Cialis and Finasteride as potential therapeutic candidates with favorable properties for managing aggressive melanoma.

This study found that in patients with genetic generalized epilepsies, certain gene variants were linked to differences in valproic acid treatment outcomes, including a higher likelihood of treatment failure, varying serum drug concentrations, and specific side effects like weight gain and hair loss.

This study found that the WNMFDDA model effectively predicts drug-disease associations, achieving high accuracy in cross-validation and confirming most candidate associations through existing databases.

In this study, researchers identified three proteins, DEFB1, HGFAC, and CYB5D2, as potential drug targets for alopecia areata, and suggested that the traditional Chinese medicine ingredient cimigenol shows promise in interacting with DEFB1 for potential treatment.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This review outlines drug repurposing as an efficient, low-cost strategy to identify new uses for existing drugs, highlighting various computational and experimental approaches as well as publicly available databases to aid in personalized pharmacotherapy.

This study proposes an AI-based method, DRGCC, using GraphSAGE and clustering constraints to predict associations between drugs and diseases, demonstrating reliable predictive performance that may aid drug repositioning efforts, including exploring drugs for COVID-19 treatment.

This article discusses drug repurposing as a strategy to find new uses for existing medications, highlighting its potential benefits like faster development and lower costs, while also addressing challenges such as drug specificity, ethical concerns, and regulatory issues.

This review explores the biological applications and pharmacokinetics of decursin, a compound isolated from Angelica gigas, highlighting its potential neuroprotective, anti-inflammatory, and anticancer properties based on in vitro and in vivo studies.

This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.

This study found that fermentation products from Bacillus sp. TC5 can effectively promote hair regrowth and improve transdermal drug absorption, suggesting their potential as eco-friendly agents in developing cosmeceuticals for hair restoration and skin repair.